University of Texas Texas AM Investment Management Co. Acquires New Holdings in Bristol Myers Squibb Company $BMY

University of Texas Texas AM Investment Management Co. bought a new position in Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, Holdings Channel reports. The institutional investor bought 76,818 shares of the biopharmaceutical company’s stock, valued at approximately $4,144,000. Bristol Myers Squibb accounts for approximately 0.6% of University of Texas Texas AM Investment Management Co.’s investment portfolio, making the stock its 25th biggest position.

Several other large investors have also recently bought and sold shares of BMY. waypoint wealth counsel bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth $1,194,000. Life Cycle Investment Partners Ltd bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $34,406,000. Axxcess Wealth Management LLC boosted its holdings in shares of Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares in the last quarter. M&G PLC raised its holdings in shares of Bristol Myers Squibb by 1.4% during the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock valued at $309,833,000 after buying an additional 97,063 shares in the last quarter. Finally, Daytona Street Capital LLC bought a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $1,362,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Trading Down 1.4%

NYSE BMY opened at $56.30 on Tuesday. The stock has a market cap of $114.97 billion, a P/E ratio of 15.82, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a 50 day simple moving average of $57.67 and a two-hundred day simple moving average of $56.99. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same quarter in the prior year, the company earned $1.80 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on BMY shares. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Piper Sandler restated an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Bank of America dropped their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Finally, HSBC raised their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.